Common Equity (Annual)

Common Equity: The sum of all common equity items.

Alnylam Pharmaceuticals, Inc. (ALNY) had Common Equity of $789.18M for the most recently reported fiscal year, ending 2025-12-31.

Quarterly Annual

Figures for fiscal year ending 2025-12-31

Income Statement Financials
Revenue	$3.71B
Net Income	$313.75M
Cost of Goods Sold	$681.87M
Gross Profit	$3.03B
Operating Expenses	$3.21B
Operating Income	$501.58M
Non-Operating Income/Expense	$-178.43M
Pre-Tax Income	$323.15M
Normalized Pre-Tax Income	$323.15M
Income after Taxes	$313.75M
Income from Continuous Operations	$313.75M
Consolidated Net Income/Loss	$313.75M
Normalized Income after Taxes	$313.75M
EBIT	$501.58M
EBITDA	$557.24M
Weighted-Average Shares Outstanding (Basic)	131.00M
Weighted-Average Shares Outstanding (Diluted)	134.68M
Earnings per Share (EPS) (Basic)	$2.39
Earnings per Share (EPS) (Diluted)	$2.33
Balance Sheet Financials
Current Assets	$4.05B
Property, Plant, and Equipment	$513.15M
Long-Term Assets	$915.67M
Total Assets	$4.97B
Current Liabilities	$1.47B
Long-Term Debt	$1.01B
Long-Term Liabilities	$2.71B
Total Liabilities	$4.18B
Common Equity	$789.18M
Tangible Shareholders Equity	$789.18M
Shareholders Equity	$789.18M
Common Shares Outstanding	132.38M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$524.08M
Cash Flow from Investing Activities	$436.33M
Cash Flow from Financial Activities	$-305.19M
Beginning Cash	$968.65M
End Cash	$1.66B
Increase/Decrease in Cash	$690.15M
Stock-Based Compensation	$348.24M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	2.76
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.56
Debt to Equity Ratio	1.28
Gross Margin	81.64%
Operating Margin	13.51%
EBIT Margin	13.51%
EBITDA Margin	15.00%
Pre-Tax Profit Margin	8.70%
Profit Margin	8.45%
Free Cash Flow	$465.38M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.75
Inventory Turnover	8.24
Receiveable Turnover	4.78
Days Sales in Receivables	76.42
Return on Equity	39.76%
Return on Tangible Equity	39.76%
Return on Assets	6.32%
Return on Investments	17.46%
Book Value Per Share	$5.96
Free Cash Flow per Share	$3.46
Operating Cash Flow per Share	$3.89

Data from Zacks Investment Research, Inc.